Maxillan Therapeutics And Chemicals (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -4.28%
- Profit Growth -50.87%
- Ebitda -11.16%
- Net Worth -4.06%
- Total Assets -3.33%
About Maxillan Therapeutics And Chemicals (Opc)
Maxillan Therapeutics And Chemicals (Opc) Private Limited (MTACOPL) is a Company incorporated in India on 07 June 2018 (Six years and eight months 9 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammed Jahanara serves as a director at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999TG2018OPC124972
-
Company No.
124972
-
Incorporation Date
07 Jun 2018
-
Date of AGM
-
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Maxillan Therapeutics And Chemicals (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Jahanara
|
Director | 07-Jun-2018 | Current |
Financial Performance of Maxillan Therapeutics And Chemicals (Opc).
Maxillan Therapeutics And Chemicals (Opc) Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 4.28% decrease. The company also saw a substantial fall in profitability, with a 50.87% decrease in profit. The company's net worth dipped by a decrease of 4.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxillan Therapeutics And Chemicals (Opc)?
Unlock access to Maxillan Therapeutics And Chemicals (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Andronovo Labs Private LimitedMohammed Jahanara is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxillan Therapeutics And Chemicals (Opc)?
Unlock and access historical data on people associated with Maxillan Therapeutics And Chemicals (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxillan Therapeutics And Chemicals (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxillan Therapeutics And Chemicals (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.